← Eichor
Study identifier: NCT04875611 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment

Condition: Nasopharyngeal Cancer  ·  Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology

PhasePhase 2
Planned participants32
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Multicentre , non-randomized, prospective clinical trial to assess efficacy of Nivolumab in treatment of nasopharyngeal cancer who progressed during or after platinum-based chemotherapy . Patients disqualified from radical therapy . The total number of patients was estimated for 32.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (4)

Klinika Hematologii z Pododziałem Chorób Naczyń Uniwersyteckiego Szpitala Klinicznego w BiałymstokuBialystok, PolandRecruiting
Klinika Hematologii i Transplantologii Gdańskiego Uniwersytetu MedycznegoGdansk, PolandRecruiting
Klinika Transplantacji Szpiku i Onkohematologii Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Oddział w GliwicachGliwice, PolandRecruiting
Klinika Hematologii i Transplantacji Szpiku, Świętokrzyskie Centrum OnkologiiKielce, PolandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04875611